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INTRODUCTION
Preeclampsia, which affects 3%-7% of all pregnancies worldwide, is the major cause of maternal and fetal morbidity and mortality in pregnancy (Lyall et al., 2013) . Symptoms of preeclampsia include onset of hypertension after week 20 of pregnancy and kidney dysfunction (Shah, 2006) . To date there is no cure for preeclampsia, and maternal symptoms are only relieved by infant delivery. Preeclampsia complications can extend beyond pregnancy with both mother and infant predisposed to cardiovascular disease later in life (Stanhewicz et al., 2017) .
A number of molecular aberrancies have been attributed to the condition but causal mechanisms of preeclampsia are largely unknown. A striking feature of preeclampsia is the late onset of symptoms (i.e., hypertension and proteinuria) after week 20 of pregnancy. This increase in blood pressure is accompanied by hypersensitivity to the vasopressor, angiotensin II (Haller et al., 1989; Shah, 2006; Stanhewicz et al., 2017) . The enhanced angiotensin II responsiveness contributes to major features of preeclampsia (i.e., elevated plasma levels of sFLT1) (Murphy and Cockrell, 2015; Zhou et al., 2007) and the increased cardiovascular risk of women who have had preeclampsia (Stanhewicz et al., 2017) . The angiotensin II hypersensitivity in preeclampsia results from protein aggregation between the vasopressor angiotensin II AT1 receptor and vasodepressor bradykinin B2 receptor (AbdAlla et al., 2001; Quitterer and AbdAlla, 2014) . At present, it is not clear whether angiotensin II hypersensitivity is a cause or bystander of preeclampsia, because angiotensin II and the angiotensin II-generating renin-angiotensin-aldosterone system are downregulated in preeclampsia (Irani and Xia, 2011) .
In search for a cause of preeclampsia, we found that increased protein complex formation between AT1 and B2 receptors was sufficient to trigger preeclampsia symptoms in pregnant mice. AT1-B2 heteromers caused vascular hypersensitivity not only to angiotensin II but also to mechano-stimulation. Even in the absence of angiotensin II, increased mechanosensitivity could activate detrimental calcium signaling at late stage pregnancy when mechanical forces increase as a consequence of continuous placental vessel wall proliferation (Burton et al., 2009 ) and/or the rapidly increasing fetalplacental mass (Bdolah et al., 2008) . Our findings could open a path to a therapy for this disease, because increased AT1-B2 receptor heteromerization was found on placental biopsies from pregnancies complicated by preeclampsia, and downregulation of AT1-B2 either by transgenic or pharmacological approaches prevented symptoms of preeclampsia in vivo.
RESULTS
The AT1-B2 Receptor Forms a Platform for Enhanced G Protein Activation, which Sensitizes the Angiotensin II Response in Vascular Smooth Muscle Cells Angiotensin II hypersensitivity is a characteristic feature of preeclampsia and caused by increased protein complex formation between the AT1 and B2 receptor (AbdAlla et al., 2001; Quitterer and AbdAlla, 2014) . In agreement with the AT1-enhancing function of the B2 receptor (AbdAlla et al., 2000) , physiological B2 receptor levels are sufficient to sensitize the endogenous angiotensin II AT1-stimulated vasopressor response ( Figures S1A-S1E ). The angiotensin II-stimulated vasopressor response was significantly lower in B2-deficient mice compared to B2-deficient mice with physiological levels of transgenic human B2 receptor expression (Figures S1A-S1E). The angiotensin II-stimulated response is mediated by the endogenous murine AT1a receptor (Ito et al., 1995) and completely blocked by the AT1-specific antagonist, candesartan ( Figure S1E ). In contrast, the B2-specific antagonist, HOE140, had no effect ( Figure S1E ). Thus, B2-mediated sensitization of the AT1 response only relies on the B2 receptor protein but does not require B2 receptor stimulation by the agonist bradykinin. As a control, the vasopressor response of another GPCR involved in preeclampsia (i.e., the endothelin ETA receptor) was not significantly enhanced by the B2 receptor ( Figure S1F ).
To investigate the impact of increased vascular AT1-B2 receptor levels, we generated transgenic mice with smooth musclespecific expression of AT1 (AGTR1) and B2 (BDKRB2) receptors under control of the SM22-alpha promoter ( Figure 1A ). The content of AT1 on aortic smooth muscle cells of two different Tg-AT1B2 mouse lines was 100.7 ± 8.6 and 110.2 ± 11.8 fmol/mg protein compared to 61.4 ± 8.8 fmol/mg of AT1 receptor in B6 controls (Figures 1B and S1G) . The moderately increased transgenic AT1 receptor level is comparable to human aortic tissue and not associated with increased systolic blood pressure (Wang et al., 2003) (cf. Figure 4 ). For comparison, the B2 receptor level in Tg-AT1B2 mouse lines was 104.3 ± 10.3 and 114.2 ± 11.5 fmol/mg protein, and the B2 level in B6 controls was 46.4 ± 8.9 fmol/mg protein (Figures 1B and S1G ]bradykinin for binding to AT1 and B2 receptors, respectively, were not significantly different between cells from transgenic and non-transgenic mice ( Figure S1G ). Increased aortic AT1 and B2 receptor protein contents in different transgenic mouse lines were confirmed by immunoblot analysis with receptor-specific antibodies (Figures 1C and S1H) .
Increased AT1-B2 protein levels caused vascular smooth muscle angiotensin II hypersensitivity and enhanced the angiotensin II-stimulated G protein activation, which was determined by proximity ligation assay (PLA) between the angiotensin II-stimulated AT1 receptor and Gng ( Figure 1D ). The angiotensin II-stimulated AT1-Gng interaction was significantly higher in Tg-AT1B2 cells compared to Tg-AT1 cells ( Figure 1D ), although, AT1 levels were comparable between Tg-AT1B2 and Tg-AT1 cells ( Figures 1B, 1C , and S1G). The B2 receptor contributed to the enhanced G protein activation mediated by AT1-B2 because angiotensin II also stimulated the B2-Gng interaction in Tg-AT1B2 cells, whereas angiotensin II did not significantly stimulate the B2-Gng interaction in Tg-AT1 cells ( Figure 1E ). Thus, the AT1-B2 receptor complex forms a platform, which mediates enhanced G protein activation.
The enhanced G protein activation led to increased signaling. Angiotensin II-stimulated cellular inositol phosphate levels were significantly higher in Tg-AT1B2 vascular smooth muscle cells compared to Tg-AT1, Tg-B2, and non-transgenic B6 cells ( Figure S1I ).
We measured the extracellular acidification rate (ECAR) to detect the angiotensin II-stimulated calcium signal-dependent Na + -H + -exchanger activation, which is involved in smooth muscle cell contraction (Berk et al., 1987) . AT1-B2-transgenic aortic smooth muscle cells showed a significantly higher angiotensin II-stimulated ECAR compared to cells from Tg-B2 and B6 mice ( Figure 1F ). The angiotensin II-stimulated ECAR of Tg-AT1B2 cells also was significantly higher compared to Tg-AT1 cells (Figure 1F) , although AT1 protein levels were comparable between Tg-AT1B2 and Tg-AT1 cells ( Figures 1B, 1C , and S1G). The calcium chelator, BAPTA-AM, prevented the AT1-B2-stimulated signal ( Figure 1F ). Thus, AT1-B2-transgenic vascular smooth muscle cells display hypersensitive angiotensin II-stimulated calcium signaling, which was attributed to the AT1-B2 receptor platform mediating enhanced G protein activation.
Increased Mechanosensitivity of AT1-B2-Transgenic Vascular Smooth Muscle Cells
Mechanical stimulation can activate the AT1 receptor in the absence of angiotensin II (Zou et al., 2004) . Hypersensitive AT1-B2 receptors enhanced the response of vascular smooth muscle cells to mechanical stimulation (Figure 2A ). The mechanical pulse triggered a significant increase in ECAR only in Tg-AT1B2 cells whereas Tg-AT1, Tg-B2, and non-transgenic (B) AT1 (top) and B2 (bottom) receptor binding sites on aortic smooth muscle cells from two different transgenic lines each of Tg-AT1, Tg-AT1B2, and Tg-B2 mice compared to B6 controls (mean ± SD; n = 5; ***p < 0.001 versus B6; Dunnett's test). (C) Aortic AT1 (top) and B2 (bottom) receptor protein levels (n = 5 per group). (D and E) Basal and angiotensin II-stimulated (+AngII, 100 nM) G protein activation of aortic smooth muscle cells from Tg-AT1 and Tg-AT1B2 mice were determined by PLA detecting the AT1-Gng (D) , and the B2-Gng (E) interaction. PLA signals (red) with DAPI-stained cell nuclei (blue) (left), and bar graphs show quantitative data (right) (mean ± SD; n = 5; ***p < 0.001; Tukey's test). (F) Angiotensin II-stimulated ECAR of aortic smooth muscle cells (mean ± SD; n = 6 technical replicates, top; n = 4 biological replicates, bottom; ***p < 0.001 and **p < 0.01 versus basal [B6] without angiotensin II; Dunnett's test; direct comparisons, Tukey's test). See also Figure S1 .
B6 cells did not respond to mechano-stimulation ( Figure 2A ). Analogous to the angiotensin II-stimulated signal, the signal stimulated by the mechanical pulse was inhibited by BAPTA-AM (Figure 2A ). Taken together, AT1-B2 confers hypersensitivity to angiotensin II and mechanical stimulation. Under conditions of increased mechanical forces (e.g., mediated by an increased fetal mass at late-stage pregnancy) AT1-B2 could thus account for enhanced vascular signaling in the absence of angiotensin II. et al., 2002; Wilson et al., 2013) .
In agreement with involvement of the AT1-B2 heteromer, the beta-arrestin-biased SII blocked the AT1-B2-mediated response to mechano-stimulation ( Figures 2B and 2D ). In contrast, the unbiased AT1 antagonist, losartan, had no effect on the mechanical pulse-induced signal triggered by AT1-B2 ( Figures 2B and 2D ). As a control, SII and losartan, both antagonized the AT1-B2-dependent signal triggered by angiotensin II ( Figures 2C and 2D ). In addition to SII, another beta-arrestinbiased AT1 agonist, TRV027 (Violin et al., 2010) , also inhibited the AT1-B2-mediated signal induced by mechano-stimulation ( Figure 2D ). In agreement with beta-arrestin-mediated AT1-B2 co-internalization (Wilson et al., 2013) , SII promoted downregulation of AT1cerulean (AT1Cer) and B2eYFP on aortic smooth muscle cells isolated from Tg-AT1Cer-B2eYFP mice whereas the unbiased losartan did not decrease cellular AT1Cer-B2eYFP levels ( Figure S2 ). Thus, SII-mediated downregulation of AT1-B2 heteromers inhibits the mechanosensitivity of AT1-B2-transgenic vascular smooth muscle cells.
Detection of AT1-B2 Heteromerization by Confocal Fluorescence Resonance Energy Transfer Imaging and Flow Cytometry
Confocal fluorescence resonance energy transfer (FRET) imaging detected AT1-B2 heteromerization on vascular smooth muscle cells from Tg-AT1cer-B2eYFP mice. There was a FRET efficiency of 26.0% ± 4.7% between AT1cer and B2eYFP (Figure 3A) . As a control, co-expression of unlabeled AT1 and unlabeled B2 significantly decreased the FRET efficiency between AT1cer and B2eYFP whereas an unrelated GPCR (i.e., the wild-type endothelin A receptor [ETA]) had no significant effect ( Figure 3A) .
In addition to confocal FRET imaging of single cells, we performed flow cytometry analysis with detection of sensitized acceptor emission as an indicator of FRET (Banning et al., 2010) . This approach determined that 94.4% ± 4.1% of AT1cer-B2eYFP double-positive aortic smooth muscle cells showed FRET ( Figure 3B ).
Together, these data demonstrate that AT1cer and B2eYFP are mainly forming heteromers on vascular smooth muscle cells isolated from double-transgenic Tg-AT1B2 mice.
Pregnant Mice with Smooth Muscle-Specific AT1-B2 Expression Develop Symptoms of Preeclampsia Are AT1-B2 heteromers sufficient to drive the symptoms of preeclampsia? Pregnant Tg-AT1B2 mice developed symptoms of preeclampsia as evidenced by hypertension on day 18 of pregnancy, proteinuria, low platelet count, and increased levels of circulating sFlt1 ( Figures 4A-4D ). Circulating sFlt1 levels of pregnant Tg-AT1B2 mice on day 18 of pregnancy were comparable to serum sFlt1 and sFLT1 levels of other mouse models of preeclampsia and human patients with severe preeclampsia (Holobotovskyy et al., 2015; De Vivo et al., 2008; Saleh et al., 2017) .
In contrast to Tg-AT1B2 mice, Tg-AT1 and Tg-B2 mice developed a phenotype of pregnancy-induced hypertension without overt preeclampsia symptoms (i.e., without proteinuria and with normal platelet count) ( Figures 4A-4C) .
Symptoms of preeclampsia in Tg-AT1B2 mice were accompanied by a significantly smaller litter size, intrauterine growth retardation, and an increased number of dead embryos compared to Tg-AT1, Tg-B2, and B6 control mice . Renal pathology causing proteinuria is another characteristic feature of preeclampsia (Stillman and Karumanchi, 2007) . Kidneys from Tg-AT1B2 mice isolated on day 18 of pregnancy showed typical preeclampsia-related glomerular injuries (i.e., glomerular endotheliosis and narrowing or occlusion of Bowman's capillary space in glomeruli) (Figures 4H and 4I) .
Increased circulating levels of endothelin-1 could contribute to preeclampsia symptoms in patients (Saleh et al., 2016) . In agreement with the endothelin-1-stimulating capacity of AT1-B2 heteromers (AbdAlla et al., 2005) , pregnant Tg-AT1B2 mice with prominent AT1-B2 heteromerization had increased plasma levels of endothelin-1 ( Figure 4J ). Endothelin-1 could mediate downregulation of plasma renin activity in preeclampsia patients (Saleh et al., 2016) . The plasma renin activity also was significantly lower in pregnant Tg-AT1B2 mice, whereas the ) induced an increase in ECAR in Tg-AT1B2 aortic smooth muscle cells. Non-transgenic B6, Tg-AT1, and Tg-B2 cells did not show a significant signal after the mechanical pulse. (B) In Tg-AT1B2 aortic smooth muscle cells, the beta-arrestin-biased agonist, SII (40 mM), prevented the increase in ECAR triggered by mechanical pulse stimulation whereas losartan (Los., 10 mM) was without effect. (C) Los. and SII blocked the angiotensin II-stimulated increase in ECAR. The AT2-specific antagonist, PD123319 (10 mM) was added as indicated. Data represent mean ± SD; n = 6 technical replicates (B and C, left) , and n = 4 biological replicates (A-C, right); ***p < 0.001 versus B6-basal (A) and basal (B and C) , **p < 0.01 versus basal; Tukey's test. (D) Effects of increasing concentrations of SII, Los., and TRV027 on total inositol phosphate levels of aortic smooth muscle cells from Tg-AT1B2 mice with angiotensin II (left), and mechano-stimulation (right). Data (mean ± SD; n = 3) are expressed as % of control, i.e., total cellular inositol phosphates of cells stimulated with 10 nM angiotensin II (1,292 ± 109 dpm; left), or after mechano-stimulation (962 ± 82 dpm; right). See also Figure S2 . activity of the angiotensin-converting enzyme (ACE) as another component of the renin-angiotensin-system was not significantly different between study groups (Figures 4K and 4L) . In these aspects, pregnant Tg-AT1B2 mice further recapitulate features of human preeclampsia (Irani and Xia, 2011) .
Analogous to preeclampsia patients (Wallukat et al., 1999) , pregnant Tg-AT1B2 mice developed autoantibodies against the AT1 receptor, which cross-reacted in ELISA with a peptide derived from the second extracellular loop of AGTR1 (Figure S3D ). These AT1-specific autoantibodies were agonistic and stimulated a calcium signal in vascular smooth muscle cells from Tg-AT1 and Tg-AT1B2 mice ( Figures S3E and S3F ). Complementary to a previous study (Chen et al., 2006) , the AT1 autoantibody-mediated signal of Tg-AT1B2 cells was prolonged and apparently did not readily desensitize. The calcium signal was mediated by the AT1 receptor because it was entirely blocked by the AT1-specific antagonist, losartan (Figures S3E and S3F) . As a control, the IgG fraction from non-transgenic B6 mice did not significantly stimulate Tg-AT1 and Tg-AT1B2 cells ( Figures S3E and S3F ). For comparison, there was a prom- inent angiotensin II-stimulated calcium signal in Tg-AT1 and Tg-AT1B2 cells (Figures S3E and S3F) . These data show that pregnant Tg-AT1B2 mice develop agonistic autoantibodies against the AT1 receptor, which could stimulate the AT1-B2 heteromer in addition to angiotensin II and mechanical stimulation.
Preeclampsia is considered (in part) to arise from maternal cardiovascular risk factors, which cause impaired trophoblast invasion of uteroplacental arteries and subsequent insufficient placental vascularization required for fetal blood and oxygen supply (Magnussen et al., 2007) . In agreement with a causal role of increased maternal AT1-B2 levels in preeclampsia, transfer of non-transgenic B6 embryos into Tg-AT1B2 foster mothers led to symptoms of preeclampsia (i.e., hypertension on day 18 of pregnancy, proteinuria, increased levels of circulating sFlt1, and decreased embryo weight) ( Figures 4M-4P ). These preeclampsia symptoms were accompanied by a strongly decreased placental labyrinth layer with reduced vascularization (Figures 4Q and 4R ). In contrast, implantation of Tg-AT1B2 embryos into non-transgenic B6 foster mothers did not cause significant preeclampsia symptoms ( Figures 4M-4R ).
Taken together, increased vascular AT1-B2 heteromers are a sufficient cause for major symptoms of preeclampsia.
Lentiviral Transduction of ARRB1-S412A
Downregulates Vascular AT1-B2 in Transgenic Mice We investigated whether downregulation of AT1-B2 receptors by beta-arrestin1 (Arrb1) counteracted symptoms of preeclampsia. We performed lentiviral transduction of ARRB1-S412A, which is the inactivation-resistant mutant of ARRB1 (Lin et al., 1997) because hyperactive AT1-B2 heteromers promoted the inactivation of Arrb1 by serine-412 phosphorylation ( Figure S4A ).
The increased aortic ARRB1-S412A/Arrb1 protein content upon lentiviral ARRB1-S412A transduction was confirmed in immunoblot ( Figure S4A ). Immunoblot analysis also showed that ARRB1-S412A normalized the aortic phospho-S412-Arrb1 content, which was increased by AT1-B2 ( Figure S4A ). Concomitantly, ARRB1-S412A/Arrb1 mediated downregulation of AT1-B2 receptor proteins ( Figure S4B ).
In the Tg-AT1B2 preeclampsia model, the ARRB1 mutant has specificity for the pathological AT1-B2 heteromer because lentiviral transduction of ARRB1-S412A did not significantly downregulate the aortic ETA receptor, which is another GPCR involved in preeclampsia ( Figure S4C ). As a control, aortic ETA receptor levels were significantly lower in pregnant Tg-AT1B2 mice compared to B6 mice, most likely as a consequence of increased plasma endothelin-1 levels, which were normalized by ARRB1-S412A ( Figures S4C and S4D ).
Downregulation of AT1-B2 by ARRB1-S412A
Counteracts the Vascular Smooth Muscle Phenotype Switch in Tg-AT1B2 Mice Vascular remodeling with a phenotype switch of smooth muscle cells from contractile to synthetic is a major factor for angiotensin II-stimulated vascular injury and hypertension (Montezano et al., 2014) . Hypersensitive vascular AT1-B2 heteromers also induced vascular remodeling and a phenotype switch of aortic smooth muscle cells from contractile to synthetic ( Figures  S4E-S4G ). Immunohistology detected this phenotype switch in the aorta of Tg-AT1B2 mice by a decreased Acta2 (smooth muscle alpha-2 actin) content of aortic medial smooth muscle cells and an increased aortic medial thickness compared to B6 controls ( Figures S4E and S4F ). Lentiviral transduction of ARRB1-S412A retarded the vascular loss of Acta2 in Tg-AT1B2 mice ( Figure S4E ) and normalized the aortic media ( Figure S4F ).
The vascular smooth muscle cell phenotype switch was further detected in Tg-AT1B2 aortas by downregulation of calponin-1 (Cnn1) and caldesmon (Cald1) and the increased expression of laminin subunit beta-1 (Lamb1) compared to B6 controls ( Figure S4G ). All these features of the synthetic smooth muscle phenotype in Tg-AT1B2 mice were counteracted by ARRB1-S412A ( Figure S4G ).
ARRB1-S412A Prevents Symptoms of Preeclampsia in Pregnant Tg-AT1B2 Mice
Concomitant with normalization of the vascular phenotype, lentiviral delivery of ARRB1-S412A dampened preeclampsia symptoms in pregnant Tg-AT1B2 mice (i.e., hypertension on day 18 of pregnancy, proteinuria, and increased serum levels of sFlt1) .
Decreased vascular RGS5 is another marker of preeclampsia in humans, and systemic deficiency of Rgs5 causes preeclampsia in mice upon stimulation with angiotensin II (Holobotovskyy et al., 2015) . The knockdown of Rgs5 was considered to enhance AT1-stimulated signaling directly (Holobotovskyy et al., 2015) . AT1-B2-transgenic mice with symptoms of preeclampsia also had decreased aortic Rgs5 levels, which were normalized by ARRB1-S412A ( Figures S4K and S4L ). Immunohistology analysis showed that Rgs5 was predominantly localized in the tunica adventitia, whereas Rgs5 was barely detectable in the vascular smooth muscle cell-containing aortic media ( Figure S4K ). Together, these findings show that the phenotype of Tg-AT1B2 mice is not restricted to the smooth muscle cell layer of the tunica media. Smooth muscle-specific AT1-B2 expression triggers systemic symptoms, which affect the tunica adventitia, the kidney, and the systemic circulation.
Placental Biopsies from Pregnancies Complicated by Preeclampsia Show an Increased Phospho-S412-ARRB1 Content and Decreased RGS5 Levels
Are mouse data relevant for human preeclampsia? Human placentas from pregnancies complicated by preeclampsia had a significantly increased content of phospho-S412-ARRB1 in the maternal basal plate compared to uncomplicated pregnancies (Figures S5A and S5B) . Variations in the placental phospho-S412-ARRB1 content in uncomplicated pregnancies could reflect the biological variability of a complex biomarker (Figure S5B) . Immunohistology localized the phospho-S412-ARRB1 in vessels of the maternal basal plate ( Figure S5C ). For comparison, the total placental ARRB1 expression level was comparable between preeclampsia cases and controls (Figure S5D) . Thus, increased ARRB1 phosphorylation on serine-412 is a characteristic feature of placentas from pregnancies complicated by preeclampsia. (B-E) Urinary albumin to creatinine ratio (B) , platelet count (C), serum sFlt1 (D) , and litter size (E) on day 18 of pregnancy. Data represent mean ± SD; n = 6 (B-D); n = 20 (E); ***p < 0.001 versus B6; *p < 0.05 versus B6 (day 0; C), and B6 (E; Dunnett's test); *p < 0.05 versus AT1B2 (D; Tukey's test). (F and G) Embryo weight (F) , and percentage (%) of dead embryos (G) . Data represent mean ± SD; n = 25 (F); n = 4-8 pregnancies (G) (***p < 0.001 versus B6; Dunnett's test). (H and I) Renal abnormalities on histological kidney sections from pregnant Tg-AT1B2 mice. The histological score was determined with H&E-stained kidney sections (H; mean ± SD; n = 6; **p < 0.01 versus B6; Dunnett's test) and (I) shows representative sections; scale bar, 50 mm. (J) Plasma endothelin-1 (ET-1) levels of Tg-AT1B2 mice (mean ± SD; n = 5; ***p < 0.001; *p < 0.05 versus B6 [day 0]; Dunnett's test). (K and L) Plasma renin activity (PRA) (K) and serum ACE activity (L) on day 18 of pregnancy (n = 5; ***p < 0.001 versus B6; Dunnett's test). (M-P) Systolic blood pressure (M), urinary albumin to creatinine ratio (N), serum sFlt1 (O), and embryo weight (P) on day 18 of pregnancy transfer of Tg-AT1B2 embryos and B6 embryos into Tg-AT1B2 foster mothers and B6 foster mothers, as indicated. Data represent mean ± SD. (n = 5, M-O; n = 22-25 [4-8 pregnancies], P; ***p < 0.001 versus B6-B6; Dunnett's test). (Q and R) Labyrinth to total placental area of day 18 placentas. Representative immunohistological sections are presented in (Q; scale bar, 600 mm), and (R) shows quantitative data (mean ± SD; n = 4 pregnancies; ***p < 0.001 versus B6-B6; Dunnett's test). See also Figure S3 .
Enhanced phosphorylation of ARRB1 on serine-412 is mediated by the Gq/11-stimulated MAPK pathway (Lin et al., 1997) , which is activated by hypersensitive AT1-B2 receptors. The Gq/11-stimulated MAPK pathway with induction of FOS is also triggered in preeclampsia (Zhao et al., 2017) and contributes to angiotensin II-stimulated vascular remodeling. In agreement with these data, placental biopsies from pregnancies complicated by preeclampsia showed increased FOS expression (Figure S5E ). Complementary to Tg-AT1B2 mice with preeclampsia (cf. Figure S4 ), placental expression levels of RGS5 were decreased in preeclampsia patients ( Figure S5F ).
These patient data show major symptoms of human preeclampsia, which are reproduced in pregnant Tg-AT1B2 mice.
A Beta-Arrestin-Biased AT1 Agonist Inhibits AT1-B2 Heteromerization and Symptoms of Preeclampsia We aimed to target AT1-B2 by a beta-arrestin-biased AT1 agonist-antagonist and chose TRV027, which has documented in vivo effects (Violin et al., 2010) and as a peptide is not expected to cross the placental barrier in substantial quantities (Pommerenke, 1936) . TRV027 inhibited the AT1-B2-mediated mechanosensitivity (cf. Figure 2D ) and downregulated AT1-B2 receptors on vascular smooth muscle cells of Tg-AT1B2 mice ( Figure 5A ). Treatment with TRV027 also prevented the increased aortic medial thickness of Tg-AT1B2 mice ( Figure 5B ).
We asked whether TRV027 decreased the aortic content of AT1-B2 heteromers. AT1-B2 heteromerization was detected in vivo on histological sections by a proximity ligation assay (PLA) applying single-domain cameloid VHH antibody fragments against AT1 and B2 receptors, respectively. Receptor specificity of cameloid VHH antibody fragments was confirmed on histological cryosections from in NOD.Scid mouse-expanded HEK cell tumors expressing either the AT1 or the B2 receptor ( Figure 5C ). Proximity ligation detected the close interaction between aortic AT1-B2 receptors of Tg-AT1B2 mice ( Figure 5D ). Downregulation of AT1-B2 by TRV027 strongly decreased the aortic content of AT1-B2 heteromers whereas another antihypertensive drug, hydralazine, had no significant effect ( Figure 5D ).
PLA is suitable to quantify protein-protein interactions closer than 40 nm (Bagchi et al., 2015) . In addition to PLA, we performed confocal FRET imaging, which detects protein-protein interactions in the range of 1-10 nm (Quitterer et al., 2011) . We applied TRITC-labeled AT1-specific and FITC-labeled B2-specific single-domain cameloid VHH antibody fragments, which detected AT1-B2 receptor co-localization on vascular smooth muscle cells from Tg-AT1B2 mice ( Figure 5E ). On aortic specimens, there was a FRET efficiency of 13.2% ± 2.5% for the AT1-B2 interaction of Tg-AT1B2 mice ( Figure 5F ). Treatment with TRV027 led to a strongly decreased FRET efficiency whereas hydralazine did not significantly alter AT1-B2 heteromerization ( Figure 5F ). As control, the presence of a 10-fold molar excess of unlabeled AT1-specific or B2-specific VHH antibody fragments significantly decreased the FRET efficiency whereas unrelated VHH fragments had no effect ( Figure 5F ).
Concomitantly with downregulation of maternal AT1-B2 heteromers, TRV027 counteracted symptoms of preeclampsia in pregnant Tg-AT1B2 mice (i.e., hypertension on day 18 of pregnancy, proteinuria, low platelet count, increased serum levels of sFlt1, and small litter size) ( Figures 5G-5K ). In contrast, hydralazine, did not significantly decrease AT1-B2 heteromerization and did not prevent major symptoms of preeclampsia ( Figures 5A, 5B, 5D , and 5F-5K), although hydralazine significantly decreased systolic blood pressure at baseline ( Figure 5G ).
Taken together, increased vascular AT1-B2 heteromerization is a sufficient cause for preeclampsia. Targeting of AT1-B2 by a beta-arrestin-biased AT1 agonist is feasible and prevents symptoms of preeclampsia.
Vascular AT1-B2 Heteromerization in the Maternal Basal Plate of Placentas from Pregnancies Complicated by Preeclampsia
We determined AT1-B2 heteromerization in human placentas from pregnancies complicated by preeclampsia. Confocal FRET imaging localized AT1-B2 receptors on maternal vessels of the placental basal plate from a pregnancy complicated by preeclampsia ( Figure 6A ). In contrast, co-localization of AT1-B2 was largely absent on a vessel of the placental basal plate from a normal pregnancy ( Figure 6A ). The FRET efficiency was 14.3% ± 3.2% between AT1-specific and B2-specific cameloid VHH antibody fragments ( Figure 6B ). The FRET efficiency of 14.3% for the AT1-B2 interaction reflects the detection of protein interactions with fluorescent dye-conjugated antibodies (Batard et al., 2002) and thus is indicative of AT1-B2 heteromerization. With a FRET efficiency of 2.9% ± 1.8%, AT1-B2 receptor heteromerization was virtually absent on maternal vessels of the placental basal plate from uncomplicated pregnancies ( Figure 6B ).
These findings show increased vascular AT1-B2 heteromerization in the maternal basal plate of placentas from pregnancies complicated by preeclampsia and an increased content of inactive phospho-S412-ARRB1.
Amlodipine and Transgenic ARRB1 Expression Promote AT1-B2 Downregulation and Prevent Symptoms of Preeclampsia in Tg-AT1B2 Mice To block the exaggerated calcium response stimulated by hyperactive vascular AT1-B2 heteromers, we applied amlodipine to inhibit the vascular L-type calcium channel of Tg-AT1B2 mice, which is activated as a consequence of enhanced calcium signaling (Kobayashi et al., 2007) . Amlodipine dampened the AT1-B2-mediated response of vascular smooth muscle cells to angiotensin II ( Figure 7A ). Amlodipine also inhibited the enhanced AT1-B2-mediated mechanosensitivity ( Figure 7B ). In contrast to amlodipine, the short-acting nifedipine with less selectivity for the vascular L-type calcium channel (Steffen, 1999) partially decreased the angiotensin II-stimulated signal but did not significantly alter the AT1-B2-stimulated mechanosensitivity, which is a direct consequence of AT1-B2 heteromerization ( Figures 7A and 7B) . In search for the underlying mechanism, we found that amlodipine led to an increased aortic Arrb1 protein content in Tg-AT1B2 mice with concomitant downregulation of vascular AT1-B2 receptors ( Figures 7C-7E ), whereas Arrb1 induction-mediated downregulation of AT1-B2 was not achieved by nifedipine (Figures 7C-7E ). Thus, specific and sustained blockade of vascular L-type calcium channels (D) PLA detection of the aortic AT1-B2 interaction of Tg-AT1B2 mice treated without (AT1B2) or with (+) TRV027 and hydralazine (scale bar, 20 mm; mean ± SD; n = 3; ***p < 0.001 versus untreated AT1B2, i.e., column 1; Dunnett's test). (E) Immunofluorescence co-localization of AT1 and B2 on vascular smooth muscle cells (VSMC) from Tg-AT1B2 mice; scale bar, 20 mm. (F) Confocal FRET imaging of the aortic AT1-B2 interaction of Tg-AT1B2 mice treated without (AT1B2) or with (+) TRV027 and hydralazine. FRET efficiencies were determined in the absence (columns 1-3) and presence of a 10-fold molar excess of unlabeled anti-AT1, anti-B2, and unrelated VHH fragments. Data represent mean ± SD. (n = 3; ***p < 0.001 versus AT1B2; Dunnett's test; scale bar, 40 mm). (G-K) Systolic blood pressure on day 0 and day 18 of pregnancy (G) , urinary albumin/creatinine ratio (H), platelet count (I), serum sFlt1 (J), and litter size (K) on day 18 of pregnancy were determined in Tg-AT1B2 mice treated without or with (+) TRV027 and hydralazine (mean ± SD; n = 6; ***p < 0.001 and **p < 0.01 versus AT1B2-d0, G; ***p < 0.001 versus AT1B2, H-K; Dunnett's test). See also Figures S4 and S5. by amlodipine seems necessary for induction of vascular Arrb1 and subsequent downregulation of AT1-B2.
Together with AT1-B2 downregulation, amlodipine prevented symptoms of preeclampsia in Tg-AT1B2 mice (i.e., hypertension on day 18 of pregnancy, proteinuria, sFlt1, low platelet count, small litter size, and embryonic death) whereas effects of nifedipine were minor ( Figures 7F-7K ). Concomitantly, amlodipine prevented the AT1-B2-mediated induction of Fos and the loss of Rgs5 (Figures 7L and 7M ). We applied both L-type calcium channel blockers at a low dose of 1 mg/kg/day, which does not alter systolic blood pressure in non-transgenic mice (Tian et al., 2011; Takahashi et al., 2013) . The low dose of nifedipine (A) Confocal FRET imaging of the AT1-B2 interaction on maternal vessels of the placental basal plate from a pregnancy complicated by preeclampsia (top) compared to a normal pregnancy (bottom); scale bar, 50 mm. (B) FRET efficiencies of the AT1-B2 interaction on maternal vessels of the placental basal plate from pregnancies complicated by preeclampsia compared to normal pregnancies (mean ± SD; n = 15; p < 0.0001; unpaired two-tailed t test). also did not affect systolic blood pressure of Tg-AT1B2 mice on day 0 and only slightly decreased systolic blood pressure on day 18 of pregnancy ( Figure 7F ).
Amlodipine prevented vascular remodeling and switched the synthetic vascular smooth muscle phenotype of Tg-AT1B2 mice toward the contractile phenotype with increased Acta2 in the tunica media and a decreased aortic medial thickness ( Figures  7N and 7O) . Restoration of the contractile vascular phenotype was accompanied by decreased aortic AT1-B2 receptor heteromerization (i.e., the FRET efficiency decreased from 12.1% on nifedipinetreated aortas to 3.7% on amlodipinetreated aortas) ( Figures 7P and 7Q ). In addition, amlodipine restored the vasculogenesis in Tg-AT1B2 placentas, which was documented by an increased area of the placental labyrinth layer (Figures S6A and S6B) . Taken together, amlodipine not only inhibits excessive AT1-B2-mediated calcium signaling but also targets the vascular AT1-B2 heteromer directly by Arrb1-mediated downregulation, blunts symptoms of preeclampsia, and restores vasculogenesis in the placental labyrinth layer.
To analyze whether a moderately increased Arrb1 level could prevent preeclampsia symptoms in Tg-AT1B2 mice, we generated Tg-ARRB1 mice with systemic expression of ARRB1 under control of the ubiquitous CMV promoter ( Figure 7R ). Transgenic ARRB1 expression in Tg-AT1B2-ARRB1 mice mediated downregulation of vascular AT1-B2 receptors ( Figures 7S and 7T ) and counteracted preeclampsia symptoms of Tg-AT1B2 mice ( Figures 7U and 7V) . Concomitantly, transgenic ARRB1 expression decreased circulating anti-AT1 receptor autoantibodies in pregnant Tg-AT1B2 mice ( Figure 7V ). Our data suggest a predominant effect of transgenic ARRB1 on the AT1-B2 heteromer, because transgenic ARRB1 expression did not significantly affect systolic blood pressure in the absence of increased aortic AT1-B2 levels (Figure 7U) . Moreover, beta-arrestin effects on other GPCRs, such 
(legend continued on next page)
as the ETA receptor, appear minor in the Tg-AT1B2 preeclampsia model (cf. Figure S4C ).
Amlodipine Treatment Effect in Pregnancies Complicated by Preeclampsia
In view of beneficial ARRB1 induction by amlodipine, treatment with amlodipine (5 mg/day) was assessed in four patients with symptoms of preeclampsia and compared to preeclampsia patients, who received antihypertensive treatment with nifedipine (slow-release, 30 mg/day) or hydralazine (80-120 mg/day). Antihypertensive treatment was initiated in frame of standard antenatal care. There were no significant differences at baseline between study groups regarding age, gestational weeks, and systolic/diastolic blood pressure at diagnosis of preeclampsia ( Figure S7A ; STAR Methods). Amlodipine, nifedipine, and hydralazine achieved comparable blood pressure control ( Figure S7A ). However, serum sFLT1 levels showed a decrease upon amlodipine treatment, whereas sFLT1 levels were not significantly altered with nifedipine and showed a significant rise upon hydralazine treatment ( Figure S7A ). It remains to be investigated whether the preeclampsia-related, continuous rise in sFLT1 with advancing gestational age (De Vivo et al., 2008) is underlying the elevated sFLT1 levels during hydralazine treatment. In addition, the amlodipine-treated group showed a significant extension of pregnancy duration (i.e., 4.25 days compared to nifedipine and 6.5 days compared to hydralazine) ( Figure S7B ). The placental content of ARRB1 was significantly higher in the amlodipine treatment group compared to patients treated with nifedipine and hydralazine ( Figure S7C ). Concomitantly, amlodipine treatment decreased placental AT1-B2 heteromerization ( Figure S7D) .
We determined the expression of preeclampsia-related genes, which are targets of AT1-B2 heteromers (i.e., FOS and RGS5) (Figures 7, S4 , and S5). The preeclampsia-induced expression of FOS was significantly decreased in placental specimens from amlodipine-treated patients compared to nifedipine and hydralazine treatment ( Figure S7E ). By contrast, the placental expression level of RGS5 was significantly higher in the amlodipine treatment group compared to nifedipine-treated and hydralazine-treated patients ( Figure S7F ). As a control, placental GAPDH levels were not significantly different between study groups ( Figure S7G ). With the caveat that pregnancy extension led to a longer treatment with amlodipine by 4-6 days, these initial data could form the basis to evaluate the treatment effect of amlodipine for preeclampsia risk reduction in a larger, randomized, controlled clinical trial.
DISCUSSION
Preeclampsia is a severe pregnancy-related complication with onset of hypertension after week 20 of pregnancy. Hypersensitivity to angiotensin II is a characteristic feature of preeclampsia (Stanhewicz et al., 2017) and mediated by an increased vascular AT1-B2 heteromerization (AbdAlla et al., 2001) . Whether angiotensin II hypersensitivity plays a causal role in the pathogenesis of preeclampsia, however, is not clear because angiotensin II levels are reduced in preeclampsia (Irani and Xia, 2011) . To investigate the impact of angiotensin II hypersensitivity on preeclampsia, we developed a transgenic mouse model with smooth muscle-specific expression of AT1-B2 receptors under control of the SM22-alpha promoter. In this model, vascular AT1-B2 receptors were predominantly localized in heteromeric complexes. Tg-AT1B2 mice developed angiotensin II hypersensitivity, which was a consequence of enhanced G protein activation mediated by the AT1-B2 receptor platform, although, additive mechanisms may be considered (e.g., receptor cross-talk). In addition, the AT1-B2 protein complex increased the sensitivity of vascular smooth muscle cells to mechanical stimulation. Increased vascular AT1-B2 heteromerization with ensuing mechanical and angiotensin II hypersensitivity was sufficient to trigger symptoms of preeclampsia in pregnant Tg-AT1B2 mice.
In addition to mice, AT1-B2 heteromerization was also a prominent feature on placental vessels of the maternal basal plate from human pregnancies complicated by preeclampsia. Moreover, hypersensitive AT1-B2 heteromers are present on mesenteric vessels and platelets of preeclamptic women (AbdAlla et al., (F) Systolic bp of Tg-AT1B2 mice on day 0 and day 18 of pregnancy (mean ± SD; n = 8; ***p < 0.001 d18+amlod. versus d18ÀAT1B2 and d18+nifed.; *p < 0.05 d18+nifed. versus d18-AT1B2 and d0+amlod. versus d0-AT1B2; Tukey's test). (O) Aortic medial thickness of Tg-AT1B2 mice on day 18 of pregnancy (mean ± SD; n = 4). (P and Q) Confocal FRET imaging of aortic AT1-B2 interaction in Tg-AT1B2 mice. Quantitative data (P; mean ± SD; n = 3) and a representative experiment (Q) are shown (scale bar, 40 mm). Green autofluorescence of elastic laminae in the amlodipine-treated aorta was detected by high-intensity donor excitation (488 nm) due to low aortic B2 receptor content (Q). (R) Transgenic construct used for generation of Tg-ARRB1 mice (left) and identification of Tg-ARRB1 founder mice by PCR genotyping. Founder no. 8 was used for further breeding. (S) Aortic ARRB1/Arrb1 content of Tg-AT1B2 and Tg-AT1B2-ARRB1 mice (mean ± SD; n = 5). (T) AT1 (left) and B2 (right) receptor binding sites of aortic smooth muscle cells from Tg-AT1B2 and Tg-AT1B2-ARRB1 mice (mean ± SD; n = 3). (U) Systolic bp on day 0 and day 18 of pregnancy (mean ± SD; n = 5; ***p < 0.0001 versus B6, Tg-ARRB1, Tg-AT1B2-ARRB1 on day 0 and day 18 of pregnancy, and Tg-AT1B2 on day 0; **p < 0.01 versus B6 and Tg-ARRB1 on day 0 and day 18, and Tg-AT1B2-ARRB1 on day 0; *p < 0.05 versus Tg-AT1B2-ARRB1 on day 18; Tukey's test). (V) Symptoms of preeclampsia in Tg-AT1B2 mice (AT1B2) on day 18 of pregnancy are counteracted by transgenic co-expression of ARRB1 in Tg-AT1B2-ARRB1 mice (mean ± SD; n = 5).
P values are indicated and were determined with the unpaired two-tailed t test in (C)-(E), (G)-(M), (O), (P), (S), (T), and (V).
See also Figures S6 and S7. 2001). Thus, our study could establish AT1-B2-mediated vascular hypersensitivity as a causative factor of human preeclampsia because increased vascular AT1-B2 heteromers are a sufficient cause of major symptoms of preeclampsia.
The transgenic model with smooth muscle-specific AT1-B2 expression develops vascular dysfunction and thereby mimics established cardiovascular risk factors for preeclampsia, which may account for impaired spiral artery remodeling in early pregnancy (Magnussen et al., 2007) . At later stages of pregnancy, exaggerated AT1-B2-mediated signaling could cause major symptoms of preeclampsia such as the generation of sFLT1 (Zhou et al., 2007) and endothelin-1 (Saleh et al., 2016 (Saleh et al., , 2017 , the downregulation of RGS5 (Holobotovskyy et al., 2013) , the induction of AT1 receptor-cross-reactive autoantibodies (Wallukat et al., 1999) with ensuing decrease in aldosterone production (Lei et al., 2018) , and the concerted expression of AT1-B2 (Kintsurashvili et al., 2001; Tan et al., 2004) . Enhanced signaling by AT1-B2 could be compensated in the first weeks of pregnancy when the angiotensin II-generating ACE is dampened (Oats et al., 1981) , and direct mechanical stimulation of AT1-B2 is minor due to low fetal mass. However, the situation will escalate at later stages of pregnancy when mechanical forces increase as a consequence of continuous placental vessel wall proliferation (Burton et al., 2009 ) and/or the rapidly increasing fetal-placental mass (Bdolah et al., 2008) . These mechanical forces are sufficient to trigger detrimental AT1-B2-mediated vascular calcium signaling even in the absence of angiotensin II, with final culmination in AT1-B2-dependent induction of hypertension and preeclampsia symptoms. Ensuing high blood pressure and ischemia are sufficient causes for AT1 receptor autoantibody induction (Chen et al., 2006) , which could further aggravate symptoms of preeclampsia.
In this scenario, ARRB1-dependent AT1-B2 downregulation could neutralize the exaggerated AT1-B2-mediated calcium response and thereby alleviate preeclampsia symptoms. In agreement with this notion, the inactivation-resistant ARRB1 mutant, ARRB1-S412A, wild-type ARRB1, and a beta-arrestinbiased AT1 agonist, TRV027 (Violin et al., 2010) , inhibited the AT1-B2 heteromer and prevented symptoms of preeclampsia in the mouse model.
Another approach of AT1-B2 targeting used the calcium channel blocker amlodipine, which also inhibited AT1-B2 by Arrb1-mediated downregulation. The long-acting amlodipine with a much higher selectivity for the vascular L-type calcium channel than nifedipine (Steffen, 1999) , could stabilize the vascular Arrb1 protein by sustained inhibition of calcium-dependent signaling pathways (Stepien et al., 2002) , which mediate protein degradation of Arrb1 (Dalle et al., 2002) . The long-acting amlodipine could also blunt the exaggerated vascular AT1-B2-mediated calcium response directly. Beneficial vascular effects of amlodipine compared to other calcium channel antagonists are well documented and could account for the decreased dementia risk, which is associated with amlodipine but not nifedipine treatment (Feldman et al., 2016) . Available data indicate that amlodipine has no negative effects on pregnancy outcome (Jiang et al., 2015) . In addition, there is preliminary evidence that preeclampsia could be reduced in high-risk patients with calcium channel blockers such as amlodipine and nifedipine (Jiang et al., 2015) .
In this aspect, calcium channel blockers are more beneficial than hydralazine (Fenakel et al., 1991) . Thus, future clinical studies could investigate whether beta-arrestin-mediated targeting of AT1-B2 (e.g., by amlodipine or the beta-arrestin-biased TRV027 in addition to aspirin) that counteracts enhanced platelet activation with overactive AT1-B2 heteromers (AbdAlla et al., 2001; Rolnik et al., 2017) could retard the onset of preeclampsia symptoms in high-risk pregnancies.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Study design of preeclampsia model
The study goal was to analyze the impact of vascular angiotensin II hypersensitivity on pregnancy outcome, notably the development of preeclampsia in a transgenic disease model. The transgenic model was established to study treatment effects of Arrb1 modulation by lentiviral transduction of ARRB1-S412A, transgenic ARRB1 expression, treatment with TRV012 and the small-molecule compound, amlodipine. These questions are based on data of the human disease, which show that systemic angiotensin II hypersensitivity is a symptom of pregnancies complicated by preeclampsia (Haller et al., 1989; Shah, 2006; Stanhewicz et al., 2017) . The underlying mechanism for angiotensin II hypersensitivity in human preeclampsia is the increased protein complex formation between the AT1 and B2 receptor proteins (AbdAlla et al., 2000 (AbdAlla et al., , 2001 Quitterer and AbdAlla, 2014) . However, to date it is not clear whether Table S1 ) N/A Primers for genotyping (see Table S1 ) angiotensin II hypersensitivity is a symptom, bystander or cause of preeclampsia. To recapitulate angiotensin II hypersensitivity in vivo and analyze its involvement in preeclampsia, mice with smooth muscle-specific AT1-B2 expression were generated, and treated with Arrb1 modulators. A sample size of n = 4-8 for evaluation of treatment effects was considered sufficient based on previous data with clonal transgenic mouse lines (Abd Alla et al., 2016) . Treatment outcomes included evaluation of preeclampsia symptoms, i.e., hypertension on day 18 of pregnancy, proteinuria, low platelet count, and circulating sFlt1 on day 18 of pregnancy. Pregnancy outcome was assessed by litter size, embryo weight, and number of viable and dead embryos. Histological assessment included evaluation of placental, aortic and kidney biopsy specimens. Pregnancy outcome was assessed in frame of phenotyping of new transgenic mouse lines. Experiments reported in the study were performed with female mice. Male mice were used for breeding.
Mice were weaned at 18-24 days after birth, separated by sex, and housed in groups (maximum of 5 mice/cage) in individually ventilated cages with nesting material and shelters under specific pathogen-free (SPF) conditions with a 12 h light/12h dark cycle. Breeding was performed with a male/female ratio of 1:1. Mice had free access to food and water. Standard social housing or pair-housing of female mice precluded randomization. Experimental groups were matched according to age and gestational age. Data acquisition was performed by a researcher, who was blinded to the genotype and treatment condition. All animal experiments were performed in accordance with the NIH guidelines, and reviewed and approved by the local authorities on animal care and use (Cantonal Veterinary Office Zurich). The study also included placental biopsy specimens of 30 pregnant women, 15 were diagnosed with preeclampsia according to ACOG criteria (details see below). Informed consent was obtained from all study participants, and the patient study was approved by the Ethics committee of the Medical Research Center (MRC), Faculty of Medicine, Ain Shams University Hospitals, Cairo.
Generation of Tg-AT1B2 preeclampsia model Transgenic mice were generated according to standard procedures (Abd Alla et al., 2016; Fu et al., 2013) . Briefly, purified, endotoxinfree, linear DNA (2ng/ml) was injected into the pro-nucleus of fertilized oocytes of super-ovulated B6 (C57BL/6J) mice, followed by oviduct transfer into pseudo-pregnant foster mice. Genotyping for stable insertion of the transgene into genomic DNA was performed by PCR with ear-punch biopsies at an age of 4 weeks. For smooth muscle-specific expression of the AT1 and B2 receptor, the cDNAs encoding AGTR1 and BDKRB2, respectively, were placed under control of the smooth muscle-specific SM22-alpha promoter (Lepore et al., 2005) . The SM22-alpha promoter sequence (Lepore et al., 2005) was amplified from genomic mouse DNA and inserted into the pcDNA3 (Invitrogen) backbone. Double-transgenic, homozygous Tg-AT1B2 mice were identified by genotyping. Controls included single-transgenic Tg-AT1, single-transgenic Tg-B2, and non-transgenic B6 mice. The study evaluated the pregnancy outcome on day 18 of pregnancy in time-mated transgenic mice of each genotype compared to non-transgenic B6 controls. Exclusion criteria were signs of abortion, which led to immediate pregnancy termination. The chosen sample size was based on similar studies of pregnancy outcome in mice (Holobotovskyy et al., 2015) . We also generated transgenic mice with systemic expression of AT1cerulean and B2eYFP with fusion of variants of the enhanced green fluorescent proteins, cerulean and eYFP, to the receptor's carboxyl terminus (Quitterer et al., 2011) . In frame of this project, we also generated transgenic Tg-ARRB1 mice with systemic expression of ARRB1. For systemic expression, cDNAs were placed under control of the ubiquitous CMV immediate-early promoter/enhancer (plasmid pcDNA3, Invitrogen). Aortic smooth muscle cells were isolated from Tg-AT1Cer-B2eYFP mice and used for FRET studies between AT1Cer-B2eYFP. In addition, we inserted the B2 receptor transgene into B2 receptor knockout mice to generate Tg-B2/B2-KO mice (B6;129S7-Bdkrb2 < tm1Jfh > Tg(CMVBDKRB2) 1Sjaa), which have the genetic background of previously generated mice with targeted inactivation of the bradykinin B2 receptor gene (Borkowski et al., 1995) .
Expression of ARRB1-S412A in female Tg-AT1B2 mice (age 11-13 weeks) was induced by lentiviral transduction of a replication-incompetent lentivirus (i.p. injection of 1x10 8 copies/mouse) on day 0 of pregnancy as confirmed by the presence of a mating plug. Age-matched, non-transgenic, time-mated female B6 mice injected with a control lentivirus served as controls. The cDNA encoding ARRB1-S412A was inserted into the plasmid pLenti4/V5-DEST Gateway Vector (Invitrogen) and the lentiviral plasmid with packaging plasmids pLP1, pLP2 and pLP/VSVG (Invitrogen) were used to generate a pseudotyped lentivirus (Abd Alla et al., 2016) . Amlodipine besylate treatment and nifedipine treatment in drinking water (1 mg/kg/day, freshly prepared every day, protected from light) was initiated at an age of 4 weeks and performed for 3 months as indicated. Treatment of threemonth-old female Tg-AT1B2 mice was performed with TRV027 (1 mg/kg/min) for 4 weeks with Alzet osmotic pumps (Alzet, model 2004 ) and compared to treatment with hydralazine (5 mg/kg/d in drinking water, freshly prepared every day). Timed mating was performed 18-20 days before the end of the treatment period. Age-matched, pregnant Tg-AT1B2 mice without treatment served as controls. The stimulated pressure response was measured by invasive hemodynamic measurements with a high-fidelity Micro-Tip Catheter Pressure Transducer (1F; Millar Instruments), which was inserted under tribromoethanol anesthesia (250 mg/kg) into the right carotid artery and advanced into the ascending aorta. Arterial pressures (upon angiotensin II or endothelin-1 stimulation; 10 mL bolus injection into the jugular vein) were recorded and analyzed with a PowerLab system (ADInstruments). Systolic blood pressure was measured with a non-invasive blood pressure measurement system, which applied a PowerLab data acquisition system coupled to a pulse transducer/cuff (MLT125 M, ADinstruments). For measurements, the restraint platform was kept at a temperature of 37 C. All animal experiments were performed in accordance with the NIH guidelines, and reviewed and approved by the local authorities on animal care and use (Cantonal Veterinary Office Zurich).
PATIENTS
The study included placental biopsy specimens of 30 pregnant women, 15 were diagnosed with preeclampsia according to ACOG criteria (American College of Obstetricians and Gynecologists) by the onset of hypertension after 20 weeks of gestation and proteinuria (> 300 mg/24h). Diagnosis of preeclampsia in these patients was made in an emergency setting followed by delivery within 24 h after diagnosis, without antenatal steroid medication. Results were only included if after 3 months after delivery blood pressure was below 140/90 mmHg, and proteinuria had disappeared. Women with chronic hypertension were excluded. Systolic blood pressure of women with preeclampsia was 167 ± 12 mmHg, and diastolic blood pressure was 103 ± 8 mm Hg. Systolic blood pressure of women with normal pregnancy was 121 ± 15 mmHg, and diastolic blood pressure was 76 ± 9 mmHg. Age was comparable between study groups, i.e., 29.0 ± 5.4 years of age (preeclampsia group) compared to 29.8 ± 5.8 years of age (normal pregnancy group). Gestational weeks at delivery were also comparable, i.e., 36.3 ± 1.4 weeks of preeclampsia group and 37.4 ± 1.7 weeks of normal pregnancy group. Informed consent was obtained from all study participants. Preeclampsia cases were included in the study based on diagnostic criteria. Controls were matched to preeclampsia cases according to age and gestational age at delivery. Placental specimens were taken at delivery. Sample size was estimated from a previous study on preeclampsia (AbdAlla et al., 2001) . Primary analysis of placental specimens was performed by a researcher, who was blinded to the experimental group.
To achieve the antihypertensive treatment goal of < 160/110 mmHg, antihypertensive treatment with amlodipine besylate (5 mg/d), slow-release nifedipine (30 mg/d), or hydralazine (80-120 mg/d) was prescribed to pregnant women with symptoms of preeclampsia, diagnosed by the onset of hypertension > 20 weeks of pregnancy and proteinuria (> 300mg/24h). There were no significant differences at baseline between the amlodipine-, nifedipine-and hydralazine-treated patients regarding age (27.8 ± 3, 26.5 ± 4, and 26.9 ± 5 years; n = 4/group), gestational weeks at diagnosis of preeclampsia (34.4 ± 1, 34.3 ± 1, and 33.8 ± 1 weeks), and systolic/diastolic blood pressure at diagnosis of preeclampsia (167 ± 4/106 ± 3, 166 ± 4/105 ± 3, and 165 ± 3/104 ± 2 mmHg). Placental biopsy specimens were taken at delivery. Study participants were matched according to age, gestational weeks at diagnosis of preeclampsia and systolic/diastolic blood pressure at diagnosis of preeclampsia. Primary outcome was assessed by a researcher, who was blinded to the allocated intervention. Informed consent was obtained from all study participants.
The patient study was approved by the Ethics committee of the Medical Research Center (MRC), Faculty of Medicine, Ain Shams University Hospitals, Cairo.
METHOD DETAILS Plasmids
For smooth muscle-specific expression in mice, cDNAs coding for AGTR1 and BDKRB2 were placed under control of the smooth muscle-specific SM22-alpha promoter. The SM22-alpha promoter was amplified by PCR from mouse genomic DNA (Lepore et al., 2005) , and inserted into the pcDNA3 backbone in replacement of the CMV promoter. For systemic expression in mice, cDNAs coding for AGTR1, BDKRB2, and ARRB1 were placed under control of the ubiquitous CMV (cytomegalovirus) immediate-early promoter/enhancer by insertion into the multiple cloning site of the pcDNA3 plasmid (Invitrogen). The mutation in ARRB1-S412A was created by overlapping PCR. For generation of a lentiviral expression plasmid, the cDNA of ARRB1-S412A was inserted into the SalI/XhoI sites of the pENTR3C plasmid (Invitrogen), followed by an LR recombination reaction between pENTR3C-ARRB1-S412A and pLenti4/V5-DEST to create pLenti4/V5-DEST-ARRB1-S412A. Plasmid DNAs and all PCR-amplified cDNAs were entirely sequenced to confirm identity of the DNA with the published DNA sequences.
Detection of FRET by confocal FRET imaging and flow cytometry with sensitized acceptor emission
The close proximity between AT1cerulean and B2eYFP on aortic smooth muscle cells isolated from transgenic Tg-AT1Cer-B2eYFP mice was detected by confocal FRET imaging and acceptor photo-bleaching using a confocal laser-scanning microscope (SP5-CLSM, Leica) as detailed previously (Quitterer et al., 2011) . Briefly, cerulean was excited at 458 nm with moderate laser power, and the emission was detected at 470-485 nm, and eYFP was excited at 495 nm (emission: 520-535 nm). The images were collected before bleaching and after eYFP (acceptor) bleaching at 514 nm with 100% laser power. Donor and acceptor fluorescence emission intensities at 470-485 nm and 520-535 nm before and after photo-bleaching of selected regions of interest were used to calculate FRET efficiencies according to the formula: E F = (I after -I before ) x 100/I after where I after is the cerulean intensity after the eYFP bleach, and I before is the cerulean intensity before the eYFP bleach (Quitterer et al., 2011) . The FRET efficiencies were calculated with the FRET-AB Wizard (Leica Application Suite Advanced Fluorescence Version 2.3.6). As a control without FRET, we used aortic smooth muscle cells with co-expression of cerulean and eYFP.
In addition, the percentage of cells with FRET was quantified by flow cytometry with a LSR Fortessa cell analyzer (Becton Dickinson) detecting the sensitized acceptor emission as an indicator for FRET similarly as described (Banning et al., 2010) . Cells co-expressing cerulean and eYFP were used to define the FRET-negative gate in flow cytometry. Cerulean was detected with the violet laser (405 nm; filter 450/50), eYFP with the blue laser (488 nm; filter 530/30), and sensitized emission with the violet laser (405 nm; filter 525/50 nm). Flow cytometry data were evaluated with FlowJo (v. 10).
The close interaction between AT1-B2 on placental cryosections from biopsy specimens of the placental basal layer from pregnancies complicated with preeclampsia compared to normal pregnancies was detected in situ by confocal FRET imaging and acceptor photo-bleaching with affinity-purified FITC-labeled anti-B2, and TRITC-labeled anti-AT1 polyclonal cameloid VHH antibody fragments. With a similar technique, the close interaction between AT1-B2 was determined by confocal FRET imaging of aortic cryosections from Tg-AT1B2 mice. Polyclonal cameloid VHH antibody fragments were generated by limited endoproteinase Glu-C (V8 protease) digestion of the affinity-purified IgG3 fraction. Immunizations of camels with antigens specific for AT1 and B2, respectively, were performed by VACSERA (Giza, Egypt). Cameloid antibody specificity for in situ detection of AT1 and B2 receptor proteins was controlled by immunohistochemistry with cryosections from HEK cell tumors isolated from NOD.Scid mice after 4 weeks of in vivo expansion of HEK cells (8x10 6 cells/200 mL of PBS) with stable expression of the AT1 and B2 receptor, respectively, as indicated (Abd Alla et al., 2010) . For confocal FRET imaging, placental (or aortic) cryosections were incubated with FITC-and TRITC-conjugated cameloid VHH antibody fragments of the respective antibodies at a concentration of 5x10 À8 M in blocking buffer (PBS, pH 7.4, supplemented with 5% bovine serum albumin fraction V) for 1 h at 37 C. After washing steps with PBS, cryosections were mounted in Aqua-Polymount (Polysciences), and imaged with a confocal laser-scanning microscope (SP5-CLSM, Leica). The FITC donor was excited at 488 nm (emission: 501-530 nm), and the TRITC acceptor was excited at 561 nm (emission 578 nm -597 nm). After image acquisition, the TRITC (acceptor) was bleached at 561 nm with 100% laser power. FRET efficiencies were calculated with the FRET-AB Wizard (Leica Application Suite Advanced Fluorescence Version 2.3.6) from images before and after acceptor photo-bleaching of selected regions of interest.
Detection of proteins by immunoblot
For immunoblot detection of aortic (and placental) proteins, aortas from transgenic and non-transgenic mice were rapidly dissected on ice, and endothelium-denuded vessels (and placental biopsy specimens) were pulverized under liquid nitrogen with pestle and mortar. Proteins were extracted for 30 min at 4 C in solubilization buffer (1% sodium deoxycholate, 0.1% SDS, 1% NP40, 5 mM EDTA, 50 mM Tris, pH 8.0, supplemented with protease/phosphatase inhibitor cocktail; Cat. No. P8340, and/or PPC1010, SigmaAldrich), followed by removal of insoluble proteins by centrifugation at 50 000 x g for 20 min at 4 C. Proteins were concentrated and delipidated by acetone/methanol precipitation (12:2; final concentration 83%) for 90 min at 4 C. The precipitate was collected by centrifugation and washed three times with 0.2 mL of ice-cold acetone. The final protein pellet was dissolved in SDS-sample buffer (2% SDS, 5% b-mercaptoethanol and 6 M urea) for 90 min at room temperature. Solubilized protein samples were stored for further use at À70 C. For immunoblot detection, proteins were separated in 7.5% or 10% urea-containing (8 M) SDS-supplemented polyacrylamide gels under reducing conditions. Proteins were transferred to PVDF membranes by wet blotting in a tank transfer cell. Receptor proteins were detected by affinity-purified F(ab) 2 fragments of receptor-specific antibodies pre-absorbed on mouse serum proteins followed by F(ab) 2 fragments (pre-absorbed on mouse serum proteins) of enzyme-coupled secondary antibodies (Jackson ImmunoResearch Laboratories), or by peroxidase-conjugated Protein A (Merck, Millipore). Bound antibodies were visualized by chemiluminescence with ECL Plus (ECL Prime) western blotting detection system.
Antibodies
For immunoblot detection of proteins and immunohistochemistry the following antibodies were used: affinity-purified antibodies against the B2 receptor, which were raised in rabbit against an antigen encompassing amino acids 356-391 of the BDKRB2 sequence (Quitterer et al., 2011) ; affinity-purified antibodies against the AT1 receptor, which were raised in rabbit against an antigen encompassing amino acids 306-359 of the ATGR1 sequence (Quitterer et al., 2011) ; affinity-purified antibodies against B2, which were raised in camel against an antigen encompassing amino acids 28-60 of the BDKRB2 sequence; affinity-purified antibodies against AT1, which were raised in camel against an antigen encompassing amino acids 1-27 of the ATGR1 sequence; polyclonal antibodies against the ETA receptor were raised in rabbit against an antigen encompassing amino acids 388-427 of the EDNRA sequence; monoclonal anti-ARRB1 antibody was raised in rabbit (clone D7Z3W; Cell Signaling Technology; Cat. No. 30036); phospho-S412-ARRB1 was raised in mouse against an epitope surrounding phospho-S412 (clone 6-24, Cat. No. 2416; Cell Signaling Technology); polyclonal antibodies against phospho-S412-ARRB1 were raised in rabbit against an epitope surrounding phospho-S412 (Abcam; Cat. No. ab4472); polyclonal antibodies against Gnb/GNB were raised in rabbit against a conserved sequence of Gnb1/GNB1, (C)-EGNVRVSRELAGHTGY (AbdAlla et al., 2004) ; Gng-specific antibodies were raised in rabbit against a conserved sequence of Gng2, SENPFREKKFFC (AbdAlla et al., 2004) ; monoclonal anti-SMA (Acta2) antibody was raised in mouse (clone 1A4; Sigma-Aldrich; Cat. No. A2547); polyclonal antibodies against RGS5 were raised in rabbit against an RGS5 fusion protein (Proteintech, Cat. No. 11590-1-AP).
Receptor-specific (anti-AGTR1, and anti-BDKRB2) polyclonal camelid antibodies were generated by immunization of two dromedaries (Camelus dromedarius) by subcutaneous injections of 0.8 mg of an antigen encompassing amino acids 1-27 of the AGTR1 sequence, and amino acids 28-60 of the BDKRB2 sequence, respectively, in complete Freund's adjuvant (total of three immunizations performed weekly) followed by 5 booster injections in incomplete Freund's adjuvant (VACSERA, Giza, Egypt). One week after the final injection, serum was collected. Serum was diluted 10-fold in 20 mM sodium phosphate (pH 7.0), and applied to protein G-Sepharoseâ (GE healthcare; Sigma Aldrich). After an incubation for 2h at 4 C, the affinity column was washed with 20 mM sodium phosphate buffer (pH 7.0). Bound antibodies were eluted from the protein G resin with 100 mM acetic acid (pH 4.0) supplemented with 500 mM NaCl, and immediately neutralized with 1 M Tris-HCl (pH 8.0). Eluted IgG3 was dialyzed against 0.1M NH 4 HCO 3 , pH 8.0. The IgG3 fraction was then incubated for 2h with endo-Glu V8 protease (1/50 ratio), which cleaves the short hinge region between the VHH and the CH2 region. After dialysis against PBS, monomeric polyclonal VHH antibody fragments were collected from the flow-through of a protein A column. Polyclonal VHH fragments were further affinity-purified on the respective antigen coupled to Affigel 10, eluted from the affinity matrix and concentrated on Amiconâ Ultra-15 PLBC Ultracel-PL (exclusion limit 3 kDa). FITC and TRITC conjugation of VHH antibody fragments was performed according to the protocol of the manufacturer (Thermo Scientific).
Immunohistology
For (immuno-)histological analysis and assessment of aortic medial thickness, serial sections (paraffin-embedded or cryosections) of the descending aorta were cut (10 mm sections, taken at intervals of 50 mm, 10-15 sections per set). Similarly, serial cryosections were cut from placental biopsy specimens and HEK cell tumors. For (immuno)-histological analysis and assessment of renal damage, serial coronal kidney sections were used. Histological assessment of biopsies was performed in a blinded manner. For assessment of renal pathology, glomeruli were scored based on Bowman's capillary space. The highest score of 5 was given to glomeruli with an intact capillary space within the Bowman's capsule whereas a score of 1 reflects complete loss of Bowman's capillary space. Immunohistology was performed with paraffin sections or cryosections. Antigen retrieval was performed by microwave heating for 30 min in antigen retrieval buffer (10 mM sodium citrate, pH 6.0 supplemented with 0.05% Tween-20), followed by incubation for 10 min at room temperature with 3.7% H 2 O 2 in PBS to inactivate endogenous peroxidases. Affinity-purified antibodies (0.5 mg/ml diluted 1:100-1:500) pre-absorbed on mouse or human serum proteins were applied in PBS supplemented with 5% bovine serum albumin fraction V. After 1 h of incubation at 37 C and washing steps in PBS supplemented with 0.05% Tween 20, the secondary antibody-peroxidase conjugate (dilution 1:500; Jackson ImmunoResearch Laboratories) was applied for 1 h at 37 C. After washing steps with PBS, bound antibody was visualized with the DAB Enhanced Liquid Substrate System (Sigma). As indicated, counterstaining with hematoxylin-eosin (HE) was performed. Paraffin sections were embedded in Polymount Xylene (Polysciences), and cryosections for immunofluorescence studies were embedded in Aqua-Polymount (Polysciences). All sections were imaged on a Leica DMI6000 microscope with a DFC420 camera.
Measurement of the extracellular acidification rate (ECAR) of aortic smooth muscle cells A Seahorse XF24 extracellular flux analyzer (Seahorse Bioscience) was used to measure the extracellular acidification rate (ECAR, i.e., the H + production rate, mpH/min) of aortic smooth muscle cells under basal conditions, after stimulation with angiotensin II or after a mechanical pulse given by the pneumatic injection of DMEM. A single mechanical pulse is sufficient to trigger a mechanosensitive response (Sullivan et al., 1997) . As indicated, aortic smooth muscle cells were incubated with amlodipine or nifedipine (1 mM) for 48 h. Aortic smooth muscle cells (20,000 cells/well) were seeded on Cell-Tak-coated (Discovery Labware, Bedford, MA) XFe24 cell culture microplates (Seahorse Biosciences) and measured in assay medium (non-buffered DMEM, XF Base Medium, supplemented with 5.5 mM glucose and 0.5 mM carnitine) after 2 h of pre-equilibration in assay medium (Abd Alla et al., 2016) . Intracellular calcium was chelated by the addition of BAPTA/AM (10 mM), as indicated. Data were recorded and evaluated with the Seahorse XFe Analyzer Software and the Wave Desktop Software (Version 2.1.0 -Version 2.3). As indicated, the extracellular acidification rates were normalized to baseline, which is the second measurement point. For comparisons between groups, H + production rates in mpH/min per mg protein are given. Experiments were performed with 6 technical replicates, and data from at least 3 different biological replicates (performed with 6 technical replicates each) are presented.
Functional assays, and gene expression analysis Vascular smooth muscle cells were isolated from the aortas of transgenic mice and non-transgenic B6 controls at an age of 6-10 days. For one vascular smooth muscle cell isolation procedure, aortas from 10-15 mice were dissected, endothelium-denuded aortas were minced with a scalpel, washed in HEPES-buffered DMEM, and digested at 37 C with collagenase. The first digestion step was discarded. In subsequent steps, the enzyme solution was exchanged every 5 min, cells were filtered through a nylon mesh, and collected in DMEM supplemented with 10% FCS. After the aortic tissue was digested, the different cell fractions were pooled, cells were collected by centrifugation, and smooth muscle cells were plated on cell culture plates (Villa-Bellosta and Hamczyk, 2015) . The urinary albumin/creatinine ratio (BCG Albumin Assay Kit, and Creatinine Assay Kit, Sigma-Aldrich), serum/ plasma sFlt1/sFLT1 levels (Mouse VEGF R1/Flt-1 Quantikine ELISA kit MVR100; human VEGF R1/Flt-1 Quantikine ELISA kit DVR100B; R&D Systems), and endothelin-1 levels (Endothelin-1 Quantikine ELISA DET100; R&D Systems) were measured with commercial kits according to the instructions of the manufacturers. Plasma renin activity was measured with the SensoLyte 520 Mouse Renin Assay kit (AnaSPEC), and serum ACE activity was assayed with the ACE kinetic assay (KK-ACK; Bü hlmann Laboratories AG). Cell-surface number of B2 receptors on intact aortic smooth muscle cells isolated from transgenic mice and non-transgenic controls was determined in HEPES-buffered DMEM (supplemented with 0.1% BSA and protease inhibitor cocktail including the ACE inhibitor enalaprilat) by saturation radioligand binding (2h at 4 C) with increasing concentrations (0.1 nM -10 nM) of [2,3-prolyl-3,4-3 (Quitterer et al., 2011) .
For determination of total cellular inositol phosphates, vascular smooth muscle cells were labeled for 12 h with 2 mCi/ml myo-[2 Figure S5 . Placental Biopsies from Pregnancies Complicated by Preeclampsia Show an Increased P-S412-ARRB1 Content, Increased FOS and Decreased RGS5 Expression, Related to Figure 5 
